|
⚲
|
| Keyboard |
| DalCor Pharmaceuticals US LLC | |
|---|---|
| Firm | |
| Fund # | |
| CIK # | 0001673368 |
| Sale | 2026-07-30 (7.0 M Offered, 7.0 M Sold) |
| Fund | |
| Phone | 5145085099 |
| Address | 677 North Washington Blvd Sarasota, FL 34236 |
| Source | [EDGAR] |
| Amount Raised ($M) |
|---|
| Company Details | |
|---|---|
| Director | |
| Custodian | |
| Auditor | |
| Marketer | |
| Broker | |
| Jurisdiction |
| Form D Offering | |
|---|---|
| Filed | 2026-08-28 (D) |
| Exemption | 506(b) |
| Duration | One year or less |
| Revenue | Decline to Disclose |
| Directors | Role | 2011 - 2026 |
|---|---|---|
| Paul Fonteyne | Director | |
| Douglas Dixon | Director |
| Comparable Firms | State | AUM |
|---|---|---|
|
Cypress Capital Group
✚
|
FL | |
|
LVNA Management LLC
✚
|
FL | |
|
Taika Capital LP
✚
|
FL | |
|
Kellner Private Fund Management LP
✚
|
FL | |
|
Kilimanjaro Advisors LLC
✚
|
FL | |
|
Harch Capital Management LLC
✚
|
FL | |
|
Assurance Mezzanine Capital LLC
✚
|
FL | |
|
Duality Advisers LP
✚
|
FL | |
|
Edinburgh Partners North America Inc
✚
|
FL | |
|
Dock Square Capital LLC
✚
|
FL |